A startup is developing a cheaper, easier way of determining whether women are genetically at risk for breast cancer, in a move that could revolutionize the way women are currently screened for the disease.
Currently, genetic testing for breast cancer risk is expensive and usually reserved for women who have a family history of the disease. But the startup Color Genomics is offering a saliva test that would cost only $249, about one-tenth the cost of many other genetic screens for breast cancer, the New York Times reports.
The saliva test analyzes BRCA1 and BRCA2, the two primary genes where mutations increase breast cancer risk, along with 17 other genes. Elad Gil, chief executive of Color Genomics, said he wants to “democratize access to genetic testing” and that the low cost of the saliva test means women could pay out of pocket if their insurance company did not cover the test.
Still, there are concerns. Some experts worry that the low cost of the test may not include a full analysis, and others raised concerns that greatly expanding the number of women tested could create confusion for those whose test results are unclear.
- The Real Reason Florida Wants to Ban AP African-American Studies, According to an Architect of the Course
- Column: Tyre Nichols' Killing Is The Result of a Diseased Culture
- Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19
- Here Are All the Movies and TV Shows That Make Up the New DCU
- TikTok's 'De-Influencing' Trend Is Here to Tell You What Stuff You Don't Need to Buy
- Column: America Goes About Juvenile Crime Sentencing All Wrong
- Why Your Tax Refund May Be Lower This Year
- Brazil Wants to Abandon a 34,000-Ton Ship at Sea. It Would be an Environmental Disaster
- The 5 Best New TV Shows Our Critic Watched in January 2023
